Fly News Breaks for February 27, 2019
Feb 27, 2019 | 08:14 EDT
Oppenheimer analyst Leland Gershell lowered Epizyme's price target to $18 from $27 after assuming coverage of the name with an Outperform rating. Impressive efficacy in r/r follicular lymphoma demonstrated by lead candidate tazemetostat should enable this drug to become the 3rd line treatment of choice in the about 20% w/EZH2-activating mutations as well as drive its use within the wild-typep opulation, he contends, adding that an NDA submission for all-comers is expected in Q4 of 2019.
News For EPZM From the Last 2 Days
There are no results for your query EPZM